非布司他上市的日期

It is the latest XOR inhibitor developed in the world. It acts on this oxidase highly selectively, reducing the synthesis of uric acid in the body and lowering the concentration of uric acid, thereby effectively treating ventilation diseases. So when will febuxostat be released on the market? This is a question that many patients have asked recently. Let’s take a look at it.

It was approved for marketing by European EMEA in October 2008, with the trade name "Adenuric". 

In February 2009, the US FDA approved it for sale under the trade name "ULORIC". 

In the 2012 American College of Rheumatology Gout Guidelines, febuxostat is recommended as a Class A recommendation for drug treatment of patients with hyperuricemia and gout, which is also the first-line drug choice. 

In June 2013, China's State Food and Drug Administration approved febuxostat for marketing in China. 

In addition, the goal of gout treatment is to reduce and maintain serum uric acid ≤6.0mg/dl. In addition to lifestyle changes, urate-lowering drugs are usually required to achieve this goal, and allopurinol is one of the most widely used drugs. Clinically, the application of allopurinol usually starts with a low dose (100 mg/d) and gradually increases the dose to achieve the target value of controlling blood uric acid. The maximum dose is 800 mg/d. There is currently no recommended dose. 

However, it has been clinically found that in some patients, allopurinol alone cannot achieve the above target value of serum uric acid, and a higher dose or combined use of other uric acid-lowering drugs may be needed. 20% of patients may experience various adverse reactions, such as rash, hypersensitivity syndrome, fever, blood system damage, abnormal liver function, renal function damage, etc., of which 5% of patients cannot tolerate the adverse reactions. Especially for patients with unsatisfactory treatment effects, intolerance of adverse reactions, and patients with renal impairment, the wide clinical application of allopurinol is limited. 

The above is the launch date of febuxostat provided to you by our medical companion travel overseas medical consulting service company. It can be seen that it has been launched in China as early as 2013, and patients can buy it with confidence.